全球IVD（體外診斷）腫瘤診斷藥的成長機會

Global Oncology Diagnostics in IVD Growth Opportunities

出版日期: 2023年07月31日 | 出版商:

Frost & Sullivan | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

利用資料驅動的解決方案、共同開發機會和分析創新，使客戶體驗到改進的產品性能、成本效益和決策能力

由於癌症罹患率上升、診斷測試技術發展、篩查測試增加以及政府支持措施等因素，全球IVD（體外診斷）腫瘤診斷市場預計將顯著成長。由於市場競爭日益激烈，各大公司都在研發方面投入巨資，以開發新的診斷測試。

個性化醫療是一個快速發展的行業，目的是根據每個患者的需求客製化癌症治療。這一改進得益於新診斷技術的發展，該技術可以識別驅動癌症進展的遺傳異常。癌症診斷主要依賴於基因組分析，它能夠檢測癌症相關基因的精確突變和突變。透過分析遺傳資料，醫療專業人員可以個性化治療策略，改善癌症患者的治療結果和預測預後。

腫瘤罹患率
按性別分類的全球年齡標準化罹患率- 十大癌症
預測假設
收入預測
收入預測分析
按地區分類的收入預測
按地區分類的收入預測分析
HRSA（美國）對癌症篩查推廣計劃的投資
按測試類型分類的收入預測
按檢查類型分類的收入預測分析
按癌症類型分類的收入預測
按癌症類型分類的收入預測分析
各地區癌症診斷檢測償付情況匯總
按用途分類的收入預測
按用途的收入預測分析

競爭分析

競爭環境
主要競爭
按級別分類的銷售佔有率
值得關注的公司：QIAGEN
值得關注的公司：Roche Diagnostics
值得關注的公司：Guardant Health
值得關注的公司：Myriad Genetics
值得關注的公司：Genomic Health
值得關注的公司：PerkinElmer
值得關注的公司：Invitae Corporation
值得關注的公司：Abbott Laboratories
值得關注的公司：Illumina
值得關注的公司：Natera
全球腫瘤診斷市場：值得關注的活動
按用途的競爭映射
腫瘤診斷市場進入者：競爭基準
全球腫瘤診斷公司：戰略挑戰

伴隨診斷

伴隨診斷：概述
CDx：市場趨勢
CDx：全球贖回概述
CDx：救贖挑戰
CDx： FDA 批准作為癌症藥物/生物標記
CDx：公司目標
伴隨診斷合作夥伴
FDA 批准/批准的伴隨診斷 IVD 設備列表

液體活體組織切片

液體活體組織切片：領先生物標記分析一步
液體活體組織切片改善篩查和分診途徑的潛力
miRNA 作為癌症生物標記
行業內液體活體組織切片公司
液體活體組織切片的監管現狀
FDA批准的液體活體組織切片測試
液體活體組織切片技術及最新趨勢
推進液體活體組織切片引進多組學以獲得全面洞察
液體活體組織切片市場機會
液體活體組織切片的商業化

充滿成長機會的宇宙

成長機會概覽
成長機會1：腫瘤篩查的成長趨勢
成長機會2：先進的綜合診斷實驗室
成長機會3：擴大液體活體組織切片測試的採用
成長機會4：AI智慧診斷
成長機會5：在亞太地區開發伴隨診斷機會
成長機會6：探索肺癌診斷和篩查機會

下一步

下一步
現在為何選擇 Frost & Sullivan？
附件清單
免責聲明

簡介目錄

Product Code: MGF8-55

By Leveraging Data-driven Solutions, Co-development Opportunities, and Assay Innovation, Clients Can Experience Enhanced Product Performance, Cost-effectiveness, and Improved Decision-making Capabilities

The global oncology diagnostics in IVD market is expected to witness significant growth, driven by an increase in cancer incidence, technological developments in diagnostic tests, the growing number of screening tests, and supportive government initiatives. Owing to the intense competition in the market, the most prominent companies are investing heavily in research and development to create new diagnostic tests.

Personalized medicine, a fast-growing industry, seeks to tailor cancer treatment to the individual needs of each patient. This improvement is aided by the development of new diagnostic technologies capable of identifying genetic abnormalities that cause cancer progression. Oncology diagnostics mainly relies on genomic profiling, which allows the detection of precise mutations and variations in cancer-related genes. Healthcare professionals can personalize treatment strategies by analyzing genetic data, resulting in improved treatment outcomes and the capacity to predict cancer patient prognosis.

Strategic Imperatives

Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Global Oncology Diagnostics in IVD Industry
Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

Scope of the Study
Segmentation by Test Type
Segmentation by Cancer Type
Segmentation by Application

Oncology Diagnostics in IVD: An Overview

Patient Care Continuum
Role of Oncology Diagnostics in Precision Medicine
The Role of Diagnostics is Crucial in the Evolving Precision Medicine Ecosystem
Trends Driving Cancer Testing

Oncology Diagnostics in IVD: Market Dynamics

Growth Metrics
Growth Drivers
Growth Restraints
Key Oncology Diagnostics Opportunities and the Impact on Business Dynamics

Oncology Diagnostics in IVD: Market Size and Forecast

Oncology Incidence Rate
Age-standardized Global Incidence Rates Per Sex-Top 10 Cancers
Forecast Assumptions
Revenue Forecast
Revenue Forecast Analysis
Revenue Forecast by Region
Revenue Forecast Analysis by Region
HRSA's Investment in the Accelerating Cancer Screening Program (the United States)
Revenue Forecast by Test Type
Revenue Forecast Analysis by Test Type
Revenue Forecast by Cancer Type
Revenue Forecast Analysis by Cancer Type
Overview of Oncology Diagnostic Test Reimbursement by Region
Revenue Forecast by Application
Revenue Forecast Analysis by Application

Competitive Analysis

Competitive Environment
Key Competitors
Revenue Share by Tier
Companies to Watch-QIAGEN
Companies to Watch-Roche Diagnostics
Companies to Watch-Guardant Health
Companies to Watch-Myriad Genetics
Companies to Watch-Genomic Health
Companies to Watch-PerkinElmer
Companies to Watch-Invitae Corporation
Companies to Watch-Abbott Laboratories
Companies to Watch-Illumina
Companies to Watch-Natera
Global Oncology Diagnostics Market: Notable Activities
Competitive Mapping by Application
Oncology Diagnostic Participants: Competitive Benchmarking
Global Oncology Diagnostics Companies: Strategic Imperatives

Companion Diagnostics

CDx Overview
CDx Market Trends
CDx Global Reimbursement Overview
CDx Reimbursement Challenges
CDx FDA Approvals for Oncology Drugs and Biomarkers
CDx Targets by Company
Companion Diagnostic Partnerships
List of FDA-cleared/approved Companion Diagnostic IVD Devices

Liquid Biopsy

Liquid Biopsy: A Step Ahead in Biomarker Analysis
Potential of Liquid Biopsies to Improve Screening and Triage Pathways
miRNAs as Potential Cancer Biomarkers
Liquid Biopsy Companies in the Industry
Liquid Biopsy Regulatory Landscape
FDA-approved Liquid Biopsy Tests
Liquid Biopsy Technology and Recent Developments
Advancing Liquid Biopsies: Embracing Multiomics for Comprehensive Insights
Liquid Biopsy Market Opportunities
Liquid Biopsy Commercialization

Growth Opportunity Universe

Growth Opportunity Summary
Growth Opportunity 1: Growing Trend of Oncology Screening
Growth Opportunity 2: Advanced, Integrated Diagnostics Labs
Growth Opportunity 3: Increased Adoption of Liquid Biopsy Testing
Growth Opportunity 4: Smart Diagnostics with AI
Growth Opportunity 5: Unlocking CDx Opportunities in APAC
Growth Opportunity 6: Unleashing Opportunities in Lung Cancer Diagnostics and Screening